<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cathepsin S is a lysosomal cysteine protease implicated in <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">tumourigenesis</z:e> with key roles in invasion and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously shown that the specific inhibition of Cathepsin S using a monoclonal antibody (Fsn0503) blocks colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated whether Cathepsin S expression levels were affected by chemotherapy in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines by RT-PCR </plain></SENT>
<SENT sid="3" pm="."><plain>Using colorectal <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e>, we examined the therapeutic benefit of Cathepsin S inhibition using Fsn0503 in combination with a metronomic dosing regimen of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 </plain></SENT>
<SENT sid="4" pm="."><plain>We analysed the effects of the combination therapy on <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> and on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> vascularisation by immunohistochemical staining of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Cathepsin S expression levels are upregulated in HCT116, LoVo, Colo205 cell lines and HUVECs after exposure to <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>The administration of Fsn0503 in combination with <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 significantly attenuated <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> in comparison to <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 alone in colorectal HCT116 <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, analysis of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> vascularisation revealed that this was also significantly disrupted by the combination treatment </plain></SENT>
<SENT sid="8" pm="."><plain>These results show that the combination of Cathepsin S inhibition with <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 enhances the therapeutic effect of the chemotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>This rationale may have clinical application in the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> upon further evaluation </plain></SENT>
</text></document>